Pharmacological interference with protein-protein interactions of akinase anchoring proteins as a strategy for the treatment of disease

Current Drug Targets

Volumn 17, Issue 10, 2016, Pages 1147-1171

  Deák, Veronika A ^a   Klussmann, Enno ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

AKAP; Compartmentalized cAMP signaling; Peptide; Peptidomimetics; PKA; Protein protein interaction; Small molecules

Indexed keywords

CALCIUM CHANNEL L TYPE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 12; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 13; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 149; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 150; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 18 ALPHA; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 18 DELTA; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 18 GAMMA; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 2; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 220; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 250; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 350; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 4; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 450; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 78; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 79; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 9; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 95; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN D; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROBEACHIN; PEPTIDOMIMETIC AGENT; PROTEIN INHIBITOR; PROTEIN OPA1; PROTEIN SKIP; PROTEIN WAVE 1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL MOLECULE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BONE MALFORMATION; BREAST CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASES; DRUG TARGETING; GENE EXPRESSION; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HIGH THROUGHPUT SCREENING; HUMAN; KALLMANN SYNDROME; KIDNEY POLYCYSTIC DISEASE; LONG QT SYNDROME; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SOLID TUMOR; UTERINE CERVIX CANCER; X RAY ANALYSIS; ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN CONFORMATION;

A KINASE ANCHOR PROTEINS; ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

EID: 84978237389     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150416114247     Document Type: Article

References (265)

1. Wu J, Brown SH, von Daake S, Taylor SS. PKA type IIalpha holoenzyme reveals a combinatorial strategy for isoform diversity. Science 2007; 318(5848): 274-9.
2. Kim C, Cheng CY, Saldanha SA, Taylor SS. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell 2007; 130(6): 1032-43.
3. Taylor SS, Zhang P, Steichen JM, Keshwani MM, Kornev AP. PKA: lessons learned after twenty years. Biochim Biophys Acta 2013; 1834(7): 1271-8.
4. Taylor SS, Ilouz R, Zhang P, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PKA. Nat Rev Mol Cell Biol 2012; 13(10): 646-58.
5. Bruystens JG, Wu J, Fortezzo A, Kornev AP, Blumenthal DK, Taylor SS. PKA RIalpha homodimer structure reveals an intermolecular interface with implications for cooperative cAMP binding and Carney complex disease. Structure 2014; 22(1): 59-69.
6. Jarnaess E, Ruppelt A, Stokka AJ, Lygren B, Scott JD, Tasken K. Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J Biol Chem 2008; 283(48): 33708-18.
7. Skroblin P, Grossmann S, Schafer G, Rosenthal W, Klussmann E. Mechanisms of protein kinase A anchoring. Int Rev Cell Mol Biol 2010; 283: 235-330.
8. Miki K, Eddy EM. Single amino acids determine specificity of binding of protein kinase A regulatory subunits by protein kinase A anchoring proteins. J Biol Chem 1999; 274(41): 29057-62.
9. Wong W, Scott JD. AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 2004; 5(12): 959-70.
10. Troger J, Moutty MC, Skroblin P, Klussmann E. A-kinase anchoring proteins as potential drug targets. British journal of pharmacology 2012; 166(2): 420-33.
11. Appert-Collin A, Baisamy L, Diviani D. Regulation of g proteincoupled receptor signaling by a-kinase anchoring proteins. J Recept Signal Transduct Res 2006; 26(5-6): 631-46.
12. Dessauer CW. Adenylyl cyclase-A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol 2009; 76(5): 935-41.
13. Cooper DM, VG Tabbasum. Adenylate cyclase-centred microdomains. Biochem J 2014; 462(2): 199-213.
14. Nijholt IM, Dolga AM, Ostroveanu A, Luiten PG, Schmidt M, Eisel UL. Neuronal AKAP150 coordinates PKA and Epacmediated PKB/Akt phosphorylation. Cell Signal 2008; 20(10): 1715-24.
15. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 2010; 35(2): 91-100.
16. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014; 13(4): 290-314.
17. Perez Lopez I, L Cariolato, D Maric, L Gillet, H Abriel, D Diviani. A-kinase anchoring protein Lbc coordinates a p38 activating signaling complex controlling compensatory cardiac hypertrophy. Mol Cell Biol 2013; 33(15): 2903-17.
18. Schillace RV, Voltz JW, Sim AT, Shenolikar S, Scott JD. Multiple interactions within the AKAP220 signaling complex contribute to protein phosphatase 1 regulation. J Biol Chem 2001; 276(15): 12128-34.
19. Oliveria SF, Dell'Acqua ML, Sather WA. AKAP79/150 anchoring of calcineurin controls neuronal L-type Ca2+ channel activity and nuclear signaling. Neuron 2007; 55(2): 261-75.
20. Flynn MP, Maizels ET, Karlsson AB, et al. Luteinizing hormone receptor activation in ovarian granulosa cells promotes protein kinase A-dependent dephosphorylation of microtubule-associated protein 2D. Mol Endocrinol 2008; 22(7): 1695-710.
21. Soni S, Scholten A, Vos MA, van Veen TA. Anchored protein kinase A signalling in cardiac cellular electrophysiology. J Cell Mol Med 2014; 18(11): 2135-46.
22. Diviani D, Soderling J, Scott JD. AKAP-Lbc anchors protein kinase A and nucleates Galpha 12-selective Rho-mediated stress fiber formation. J Biol Chem 2001; 276(47): 44247-57.
23. Alto NM, Soderling J, Scott JD. Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics. J Cell Biol 2002; 158(4): 659-68.
24. Gelman IH. The role of SSeCKS/gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci 2002; 7: d1782-97.
25. Hundsrucker C, Klussmann E. Direct AKAP-mediated proteinprotein interactions as potential drug targets. Handbook Exp Pharmacol 2008;(186): 483-503.
26. Carnegie GK, Soughayer J, Smith FD, et al. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell 2008; 32(2): 169-79.
27. Mauban JR, O'Donnell M, Warrier S, Manni S, Bond M. AKAPscaffolding proteins and regulation of cardiac physiology. Physiology (Bethesda) 2009; 24: 78-87.
28. Diviani D, Maric D, Perez Lopez I, Cavin S, Del Vescovo CD. Akinase anchoring proteins: molecular regulators of the cardiac stress response. Biochim Biophys Acta 2013; 1833(4): 901-8.
29. Carr DW, Newell AE. The role of A-kinase anchoring proteins (AKaps) in regulating sperm function. Soc Reprod Fertil Suppl 2007; 63: 135-41.
30. Luconi M, Cantini G, Baldi E, Forti G. Role of a-kinase anchoring proteins (AKAPs) in reproduction. Front Biosci (Landmark Ed) 2011; 16: 1315-30.
31. Vijayaraghavan S, Goueli SA, Davey MP, Carr DW. Protein kinase A-anchoring inhibitor peptides arrest mammalian sperm motility. J Biol Chem 1997; 272(8): 4747-52.
32. Lester LB, Langeberg LK, Scott JD. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci USA 1997; 94(26): 14942-7.
33. Torgersen KM, Aandahl EM, Tasken K. Molecular architecture of signal complexes regulating immune cell function. Handbook Exp Pharmacol 2008;(186): 327-63.
34. Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W. Protein kinase A anchoring proteins are required for vasopressinmediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem 1999; 274(8): 4934-8.
35. Patel HH, Hamuro LL, Chun BJ, et al. Disruption of protein kinase A localization using a trans-activator of transcription (TAT)- conjugated A-kinase-anchoring peptide reduces cardiac function. J Biol Chem 2010; 285(36): 27632-40.
36. Christian F, Szaszak M, Friedl S, et al. Small molecule AKAPprotein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J Biol Chem 2011; 286(11): 9079-96.
37. Fink MA, DR Zakhary, JA Mackey, et al. AKAP-mediated targeting of protein kinase a regulates contractility in cardiac myocytes. Circ Res 2001; 88(3): 291-7.
38. Lygren B, Carlson CR, Santamaria K, et al. AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep 2007; 8(11): 1061-7.
39. Soni S, Scholten A, Vos MA, van Veen TA. Anchored protein kinase A signalling in cardiac cellular electrophysiology. J Cell Mol Med 2014.
40. Lin C, Guo X, Lange S, et al. Cypher/ZASP is a novel A-kinase anchoring protein. J Biol Chem 2013; 288(41): 29403-13.
41. Jones BW, Brunet S, Gilbert ML, et al. Cardiomyocytes from AKAP7 knockout mice respond normally to adrenergic stimulation. Proc Natl Acad Sci USA 2012; 109(42): 17099-104.
42. Nichols CB, Rossow CF, Navedo MF, et al. Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ Res 2010; 107(6): 747-56.
43. Weiss S, Oz S, Benmocha A, Dascal N. Regulation of cardiac Ltype Ca(2)(+) channel CaV1.2 via the beta-adrenergic-cAMPprotein kinase A pathway: old dogmas, advances, and new uncertainties. Circ Res 2013; 113(5): 617-31.
44. Diviani D. Modulation of cardiac function by A-kinase anchoring proteins. Curr Opin Pharmacol 2008; 8(2): 166-73.
45. del Vescovo CD, Cotecchia S, Diviani D. A-kinase-anchoring protein-Lbc anchors IkappaB kinase beta to support interleukin-6- mediated cardiomyocyte hypertrophy. Mol Cell Biol 2013; 33(1): 14-27.
46. Cariolato L, Cavin S, Diviani D. A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling complex involved in alpha1-adrenergic receptor-induced p38 activation. J Biol Chem 2011; 286(10): 7925-37.
47. Carnegie GK, Smith FD, McConnachie G, Langeberg LK, Scott JD. AKAP-Lbc nucleates a protein kinase D activation scaffold. Mol Cell 2004; 15(6): 889-99.
48. Taglieri DM, Johnson KR, Burmeister BT, et al. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy. J Mol Cell Cardiol 2014; 66: 27-40.
49. Appert-Collin A, Cotecchia S, Nenniger-Tosato M, Pedrazzini T, Diviani D. The A-kinase anchoring protein (AKAP)-Lbc-signaling complex mediates alpha1 adrenergic receptor-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2007; 104(24): 10140-5.
50. Cavin S, Maric D, Diviani D. A-kinase anchoring protein-Lbc promotes pro-fibrotic signaling in cardiac fibroblasts. Biochim Biophys Acta 2014; 1843(2): 335-45.
51. Diviani D, Dodge-Kafka KL, Li J, Kapiloff MS. A-kinase anchoring proteins: scaffolding proteins in the heart. Am J Physiol Heart Circ Physiol 2011; 301(5): H1742-53.
52. Aye TT, Soni S, van Veen TA, et al. Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol 2012; 52(2): 511-8.
53. Zakhary DR, Moravec CS, Bond M. Regulation of PKA binding to AKAPs in the heart: alterations in human heart failure. Circulation 2000; 101(12): 1459-64.
54. Hundsrucker C, Krause G, Beyermann M, et al. High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides. Biochem J 2006; 396(2): 297-306.
55. Lygren B, Tasken K. The potential use of AKAP18delta as a drug target in heart failure patients. Expert Opin Biol Ther 2008; 8(8): 1099-108.
56. Klussmann E, Rosenthal W. Role and identification of protein kinase A anchoring proteins in vasopressin-mediated aquaporin-2 translocation. Kidney Int 2001; 60(2): 446-9.
57. Nedvetsky PI, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E. Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol 2009;(190): 133-57.
58. Szaszak M, Christian F, Rosenthal W, Klussmann E. Compartmentalized cAMP signalling in regulated exocytic processes in nonneuronal cells. Cell Signal 2008; 20(4): 590-601.
59. Sasaki S. Aquaporin 2: from its discovery to molecular structure and medical implications. Mol Aspects Med 2012; 33(5-6): 535-46.
60. Verkman AS, Anderson MO, Papadopoulos MC. Aquaporins: important but elusive drug targets. Nat Rev Drug Discov 2014; 13(4): 259-77.
61. Nedvetsky PI, Tabor V, Tamma G, et al. Reciprocal regulation of aquaporin-2 abundance and degradation by protein kinase A and p38-MAP kinase. J Am Soc Nephrol 2010; 21(10): 1645-56.
62. King LS, D Kozono, P Agre. From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol 2004; 5(9): 687-98.
63. Klussmann E, Maric K, Rosenthal W. The mechanisms of aquaporin control in the renal collecting duct. Rev Physiol Biochem Pharmacol 2000; 141: 33-95.
64. Valenti G, Procino G, Tamma G, Carmosino M, Svelto M. Minireview: aquaporin 2 trafficking. Endocrinology 2005; 146(12): 5063-70.
65. Robben JH, Knoers NV, Deen PM. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2006; 291(2): F257-70.
66. Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med 2006; 119(12 Suppl 1): S11-6.
67. Kwon TH, J Nielsen, HB Moller, RA Fenton, S Nielsen, J Frokiaer. Aquaporins in the kidney. Handbook Exp Pharmacol 2009;(190): 95-132.
68. Schrier RW, Cadnapaphornchai MA. Renal aquaporin water channels: from molecules to human disease. Prog Biophys Mol Biol 2003; 81(2): 117-31.
69. Henn V, Edemir B, Stefan E, et al. Identification of a novel Akinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J Biol Chem 2004; 279(25): 26654-65.
70. Henn V, Stefan E, Baillie GS, Houslay MD, Rosenthal W, Klussmann E. Compartmentalized cAMP signalling regulates vasopressin- mediated water reabsorption by controlling aquaporin-2. Biochem Soc Trans 2005; 33(Pt 6): 1316-8.
71. Okutsu R, Rai T, Kikuchi A, et al. AKAP220 colocalizes with AQP2 in the inner medullary collecting ducts. Kidney Int 2008; 74(11): 1429-33.
72. Stefan E, Wiesner B, Baillie GS, et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol 2007; 18(1): 199-212.
73. Mekahli D, Parys JB, Bultynck G, Missiaen L, De Smedt H. Polycystins and cellular Ca2+ signaling. Cell Mol Life Sci 2013; 70(15): 2697-712.
74. Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014; 25(1): 18-32.
75. Streets AJ, Wessely O, Peters DJ, Ong AC. Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation. Hum Mol Genet 2013; 22(10): 1924-39.
76. Choi YH, Suzuki A, Hajarnis S, et al. Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci USA 2011; 108(26): 10679-84.
77. Leech CA, Dzhura I, Chepurny OG, et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells. Prog Biophys Mol Biol 2011; 107(2): 236-47.
78. Dyachok O, Isakov Y, Sagetorp J, Tengholm A. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells. Nature 2006; 439(7074): 349-52.
79. Ni Q, Ganesan A, Aye-Han NN, et al. Signaling diversity of PKA achieved via a Ca2+-cAMP-PKA oscillatory circuit. Nat Chem Biol 2011; 7(1): 34-40.
80. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
81. Tengholm A. Cyclic AMP dynamics in the pancreatic beta-cell. Ups J Med Sci 2012; 117(4): 355-69.
82. Fraser ID, Tavalin SJ, Lester LB, et al. A novel lipid-anchored Akinase Anchoring Protein facilitates cAMP-responsive membrane events. EMBO J 1998; 17(8): 2261-72.
83. Lester LB, Faux MC, Nauert JB, Scott JD. Targeted protein kinase A and PP-2B regulate insulin secretion through reversible phosphorylation. Endocrinology 2001; 142(3): 1218-27.
84. Josefsen K, Lee YC, Thams P, Efendic S, Nielsen JH. AKAP 18 alpha and gamma have opposing effects on insulin release in INS- 1E cells. FEBS Lett 2010; 584(1): 81-5.
85. Hinke SA, Navedo MF, Ulman A, et al. Anchored phosphatases modulate glucose homeostasis. EMBO J 2012; 31(20): 3991-4004.
86. Teo AK, Kulkarni RN. Setting sail for glucose homeostasis with the AKAP150-PP2B-anchor. EMBO J 2012; 31(20): 3956-7.
87. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494(7436): 256-60.
88. Yang J, Li JH, Wang J, Zhang CY. Molecular modeling of BAD complex resided in a mitochondrion integrating glycolysis and apoptosis. J Theor Biol 2010; 266(2): 231-41.
89. Danial NN, Gramm CF, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424(6951): 952-6.
90. Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356(6371): 721-2.
91. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003; 301(5631): 370-3.
92. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37(6): 667-87.
93. Sarabu R, Bizzarro FT, Corbett WL, et al. Discovery of piragliatin- -first glucokinase activator studied in type 2 diabetic patients. J Med Chem 2012; 55(16): 7021-36.
94. Pidoux G, Witczak O, Jarnaess E, et al. Optic atrophy 1 is an Akinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis. EMBO J 2011; 30(21): 4371-86.
95. Ohsaki Y, Suzuki M, Fujimoto T. Open questions in lipid droplet biology. Chem Biol 2014; 21(1): 86-96.
96. Rogne M, Tasken K. Compartmentalization of cAMP Signaling in Adipogenesis, Lipogenesis, and Lipolysis. Horm Metab Res 2014.
97. Bridges D, MacDonald JA, Wadzinski B, Moorhead GB. Identification and characterization of D-AKAP1 as a major adipocyte PKA and PP1 binding protein. Biochem Biophys Res Commun 2006; 346(1): 351-7.
98. Marrades MP, Gonzalez-Muniesa P, Martinez JA, Moreno-Aliaga MJ. A dysregulation in CES1, APOE and other lipid metabolismrelated genes is associated to cardiovascular risk factors linked to obesity. Obes Facts 2010; 3(5): 312-8.
99. Merrill RA, Strack S. Mitochondria: a kinase anchoring protein 1, a signaling platform for mitochondrial form and function. Int J Biochem Cell Biol 2014; 48: 92-6.
100. Ginsberg MD, Feliciello A, Jones JK, Avvedimento EV, Gottesman ME. PKA-dependent binding of mRNA to the mitochondrial AKAP121 protein. J Mol Biol 2003; 327(4): 885-97.
101. Grozdanov PN, Stocco DM. Short RNA molecules with high binding affinity to the KH motif of A-kinase anchoring protein 1 (AKAP1): implications for the regulation of steroidogenesis. Mol Endocrinol 2012; 26(12): 2104-17.
102. Oonishi T, Sakashita K, Uyesaka N. Regulation of red blood cell filterability by Ca2+ influx and cAMP-mediated signaling pathways. Am J Physiol 1997; 273(6 Pt 1): C1828-34.
103. Hines PC, Zen Q, Burney SN, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 2003; 101(8): 3281-7.
104. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest 1980; 65(1): 154-60.
105. Ballas SK, Mohandas N. Pathophysiology of vaso-occlusion. Hematol Oncol Clin North Am 1996; 10(6): 1221-39.
106. Maciaszek JL, Andemariam B, Abiraman K, G Lykotrafitis K. AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy. Biophys J 2014; 106(6): 1258-67.
107. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000; 109(2): 322-7.
108. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
109. Smith FD, Langeberg LK, Cellurale C, et al. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat Cell Biol 2010; 12(12): 1242-9.
110. Klussmann E, Edemir B, Pepperle B, et al. Ht31: the first protein kinase A anchoring protein to integrate protein kinase A and Rho signaling. FEBS Lett 2001; 507(3): 264-8.
111. Lenoir M, Sugawara M, Kaur J, Ball LJ, Overduin M. Structural insights into the activation of the RhoA GTPase by the Lbc oncoprotein. J Biol Chem 2014; 289(34): 23992-4004.
112. Wirtenberger M, Tchatchou S, Hemminki K, et al. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis 2006; 27(3): 593-8.
113. Rogers R, Norian J, Malik M, et al. Mechanical homeostasis is altered in uterine leiomyoma. Am J Obstet Gynecol 2008; 198(4): 474 e1-11.
114. Zheng Y, Olson MF, Hall A, Cerione RA, Toksoz D. Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J Biol Chem 1995; 270(16): 9031-4.
115. Toksoz D, Williams DA. Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction products. Oncogene 1994; 9(2): 621-8.
116. Olson MF, Sterpetti P, Nagata K, Toksoz D, Hall A. Distinct roles for DH and PH domains in the Lbc oncogene. Oncogene 1997; 15(23): 2827-31.
117. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70(3): 389-99.
118. Sterpetti P, Hack AA, Bashar MP, et al. Activation of the Lbc Rho exchange factor proto-oncogene by truncation of an extended C terminus that regulates transformation and targeting. Mol Cell Biol 1999; 19(2): 1334-45.
119. Diviani D, Abuin L, Cotecchia S, Pansier L. Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J 2004; 23(14): 2811-20.
120. Ridley AJ, Hall A. Distinct patterns of actin organization regulated by the small GTP-binding proteins Rac and Rho. Cold Spring Harb Symp Quant Biol 1992; 57: 661-71.
121. Caretta A, Mucignat-Caretta C. Protein kinase a in cancer. Cancers (Basel) 2011; 3(1): 913-26.
122. Sechi AS, Wehland J. ENA/VASP proteins: multifunctional regulators of actin cytoskeleton dynamics. Front Biosci 2004; 9: 1294-310.
123. Troger J, Moutty MC, Skroblin P, Klussmann E. A-kinase anchoring proteins as potential drug targets. Br J Pharmacol 2012; 166(2): 420-33.
124. Gold MG, Gonen T, Scott JD. Local cAMP signaling in disease at a glance. J Cell Sci 2013; 126(Pt 20): 4537-43.
125. Esseltine JL, Scott JD. AKAP signaling complexes: pointing towards the next generation of therapeutic targets? Trends Pharmacol Sci 2013; 34(12): 648-55.
126. Yang MH, Hu ZY, Xu C, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim Biophys Acta 2015; 1852(1): 166-74.
127. Hayashi M, Nomoto S, Kanda M, et al. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. J Surg Oncol 2012; 105(4): 381-6.
128. Kuijjer ML, Rydbeck H, Kresse SH, et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012; 51(7): 696-706.
129. Kim DH, Lee ST, Won HH, et al. A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood 2011; 117(25): 6906-11.
130. Jo UH, Whang YM, Sung JS, Kim YH. Methylation of AKAP12{alpha} promoter in lung cancer. Anticancer Res 2010; 30(11): 4595-600.
131. Liu W, Guan M, Su B, et al. Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylationsensitive high resolution melting: Correlation with Duke's stage. Cancer Biol Ther 2010; 9(11): 862-71.
132. Wu W, Zhang J, Yang H, Shao Y, Yu B. Examination of AKAP12 promoter methylation in skin cancer using methylation-sensitive high-resolution melting analysis. Clin Exp Dermatol 2011; 36(4): 381-5.
133. Su B, Gao L, Meng F, Guo LW, Rothschild J, Gelman IH. Adhesion- mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene 2013; 32(16): 2016-26.
134. Su B, Bu Y, Engelberg D, Gelman IH. SSeCKS/Gravin/ AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway. J Biol Chem 2010; 285(7): 4578-86.
135. Mostafa MR, Yahia RS, Abd El Messih HM, El-Sisy E, El Ghannam DM. Gravin gene expression in acute myeloid leukemia. Med Oncol 2013; 30(2): 548.
136. Turner RM, Foster JA, Gerton GL, Moss SB, Patrizio P. Molecular evaluation of two major human sperm fibrous sheath proteins, prohAKAP82 and hAKAP82, in stump tail sperm. Fertil Steril 2001; 76(2): 267-74.
137. Miki K, Willis WD, Brown PR, Goulding EH, Fulcher KD, Eddy EM. Targeted disruption of the Akap4 gene causes defects in sperm flagellum and motility. Dev Biol 2002; 248(2): 331-42.
138. Chiriva-Internati M, Ferrari R, Yu Y, et al. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol 2008; 140(4): 465-8.
139. Chiriva-Internati M, Yu Y, Mirandola L, et al. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate 2012; 72(1): 12-23.
140. Agarwal S, Saini S, Parashar D, et al. The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. Oncoimmunology 2013; 2(5): e24270.
141. Saini S, Agarwal S, Sinha A, et al. Gene silencing of A-kinase anchor protein 4 inhibits cervical cancer growth in vitro and in vivo. Cancer Gene Ther 2013; 20(7): 413-20.
142. Hofmann B, Nishanian P, Nguyen T, Insixiengmay P, Fahey JL. Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes. Proc Natl Acad Sci USA 1993; 90(14): 6676-80.
143. Aandahl EM, Aukrust P, Skalhegg BS, et al. Protein kinase A type I antagonist restores immune responses of T cells from HIVinfected patients. FASEB J 1998; 12(10): 855-62.
144. Tasken K, Stokka AJ. The molecular machinery for cAMPdependent immunomodulation in T-cells. Biochem Soc Trans 2006; 34(Pt 4): 476-9.
145. Kammer GM. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 1988; 9(7-8): 222-9.
146. Scott JD, Dessauer CW, Tasken K. Creating order from chaos: cellular regulation by kinase anchoring. Annu Rev Pharmacol Toxicol 2013; 53: 187-210.
147. Liang WS, Maddukuri A, Teslovich TM, et al. Therapeutic targets for HIV-1 infection in the host proteome. Retrovirology 2005; 2: 20.
148. Lemay J, Maidou-Peindara P, Cancio R, et al. AKAP149 binds to HIV-1 reverse transcriptase and is involved in the reverse transcription. J Mol Biol 2008; 383(4): 783-96.
149. Ruppelt A, Mosenden R, Gronholm M, et al. Inhibition of T cell activation by cyclic adenosine 5'-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol 2007; 179(8): 5159-68.
150. Lone AM, Tasken K. Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol 2013; 4: 130.
151. Rahmouni S, Aandahl EM, Nayjib B, et al. Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirusinduced T-cell dysfunction in mice. Biochem J 2004; 384(Pt 3): 469-76.
152. Mosenden R, Singh P, Cornez I, et al. Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. J Immunol 2011; 186(9): 5119-30.
153. Roy NH, Lambele M, Chan J, Symeonides M, Thali M. Ezrin is a component of the HIV-1 virological presynapse and contributes to the inhibition of cell-cell fusion. J Virol 2014; 88(13): 7645-58.
154. Singh M, Singh P, Vaira D, et al. The RIAD peptidomimetic inhibits HIV-1 replication in humanized NSG mice. Eur J Clin Invest 2013.
155. Schillace RV, Miller CL, Pisenti N, et al. A-kinase anchoring in dendritic cells is required for antigen presentation. PLoS One 2009; 4(3): e4807.
156. Bagley KC, Abdelwahab SF, Tuskan RG, Fouts TR, Lewis GK. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J Leukoc Biol 2002; 72(5): 962-9.
157. Schillace RV, Miller CL, Carr DW. AKAPs in lipid rafts are required for optimal antigen presentation by dendritic cells. Immunol Cell Biol 2011; 89(5): 650-8.
158. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009; 4: 435-59.
159. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8(3): 183-92.
160. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352(19): 1967-76.
161. Oenema TA, Kolahian S, Nanninga JE, et al. Pro-inflammatory mechanisms of muscarinic receptor stimulation in airway smooth muscle. Respir Res 2010; 11: 130.
162. Poppinga WJ, Munoz-Llancao P, Gonzalez-Billault C, Schmidt M. A-kinase anchoring proteins: Cyclic AMP compartmentalization in neurodegenerative and obstructive pulmonary diseases. Br J Pharmacol 2014.
163. Oldenburger A, Roscioni SS, Jansen E, et al. Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. PLoS One 2012; 7(2): e31574.
164. Roscioni SS, Kistemaker LE, Menzen MH, et al. PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir Res 2009; 10: 88.
165. Roscioni SS, Prins AG, Elzinga CR, et al. Protein kinase A and the exchange protein directly activated by cAMP (Epac) modulate phenotype plasticity in human airway smooth muscle. Br J Pharmacol 2011; 164(3): 958-69.
166. Horvat SJ, Deshpande DA, Yan H, et al. A-kinase anchoring proteins regulate compartmentalized cAMP signaling in airway smooth muscle. FASEB J 2012; 26(9): 3670-9.
167. Bliss TV, Collingridge GL. A synaptic model of memory: longterm potentiation in the hippocampus. Nature 1993; 361(6407): 31-9.
168. Martin SJ, Morris RG. New life in an old idea: the synaptic plasticity and memory hypothesis revisited. Hippocampus 2002; 12(5): 609-36.
169. Tunquist BJ, Hoshi N, Guire ES, et al. Loss of AKAP150 perturbs distinct neuronal processes in mice. Proc Natl Acad Sci USA 2008; 105(34): 12557-62.
170. Rosenmund C, Carr DW, Bergeson SE, Nilaver G, Scott JD, Westbrook GL. Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons. Nature 1994; 368(6474): 853-6.
171. Sanderson JL, Dell'Acqua ML. AKAP signaling complexes in regulation of excitatory synaptic plasticity. Neuroscientist 2011; 17(3): 321-36.
172. Jayakar SS, Pugh PC, Dale Z, Starr ER, Cole S, JF Margiotta. PACAP induces plasticity at autonomic synapses by nAChRdependent NOS1 activation and AKAP-mediated PKA targeting. Mol Cell Neurosci 2014; 63C: 1-12.
173. Joiner ML, Lise MF, Yuen EY, et al. Assembly of a beta2- adrenergic receptor-GluR1 signalling complex for localized cAMP signalling. EMBO J 2010; 29(2): 482-95.
174. Balijepalli RC, Foell JD, Hall DD, Hell JW, Kamp TJ. Localization of cardiac L-type Ca(2+) channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation. Proc Natl Acad Sci USA 2006; 103(19): 7500-5.
175. Davare MA, Avdonin V, Hall DD, et al. A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Science 2001; 293(5527): 98-101.
176. Wang D, Govindaiah G, Liu R, De Arcangelis V, Cox CL, Xiang YK. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J 2010; 24(9): 3511-21.
177. Schnizler K, Shutov LP, Van Kanegan MJ, et al. Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons. J Neurosci 2008; 28(19): 4904-17.
178. Zhang X, Li L, McNaughton PA. Proinflammatory mediators modulate the heat-activated ion channel TRPV1 via the scaffolding protein AKAP79/150. Neuron 2008; 59(3): 450-61.
179. Jeske NA, Patwardhan AM, Ruparel NB, Akopian AN, Shapiro MS, Henry MA. A-kinase anchoring protein 150 controls protein kinase C-mediated phosphorylation and sensitization of TRPV1. Pain 2009; 146(3): 301-7.
180. Por ED, Samelson BK, Belugin S, Akopian AN, Scott JD, Jeske NA. PP2B/calcineurin-mediated desensitization of TRPV1 does not require AKAP150. Biochem J 2010; 432(3): 549-56.
181. Efendiev R, Bavencoffe A, Hu H, Zhu MX, Dessauer CW. Scaffolding by A-kinase anchoring protein enhances functional coupling between adenylyl cyclase and TRPV1 channel. J Biol Chem 2013; 288(6): 3929-37.
182. Kaminsky EB, Kaul V, Paschall J, et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet Med 2011; 13(9): 777-84.
183. Anney R, Klei L, Pinto D, et al. A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet 2010; 19(20): 4072-82.
184. Prasad A, Merico D, Thiruvahindrapuram B, et al. A discovery resource of rare copy number variations in individuals with autism spectrum disorder. G3 (Bethesda) 2012; 2(12): 1665-85.
185. Wang X, Herberg FW, Laue MM, et al. Neurobeachin: A protein kinase A-anchoring, beige/Chediak-higashi protein homolog implicated in neuronal membrane traffic. J Neurosci 2000; 20(23): 8551-65.
186. Volders K, Nuytens K, Creemers JW. The autism candidate gene Neurobeachin encodes a scaffolding protein implicated in membrane trafficking and signaling. Curr Mol Med 2011; 11(3): 204-17.
187. Nuytens K, Tuand K, Di Michele M, et al. Platelets of mice heterozygous for neurobeachin, a candidate gene for autism spectrum disorder, display protein changes related to aberrant protein kinase A activity. Mol Autism 2013; 4(1): 43.
188. Dahl JP, Wang-Dunlop J, Gonzales C, Goad ME, Mark RJ, Kwak SP. Characterization of the WAVE1 knock-out mouse: implications for CNS development. J Neurosci 2003; 23(8): 3343-52.
189. Soderling SH, Langeberg LK, Soderling JA, et al. Loss of WAVE- 1 causes sensorimotor retardation and reduced learning and memory in mice. Proc Natl Acad Sci USA 2003; 100(4): 1723-8.
190. Ceglia I, Kim Y, Nairn AC, Greengard P. Signaling pathways controlling the phosphorylation state of WAVE1, a regulator of actin polymerization. J Neurochem 2010; 114(1): 182-90.
191. Yokoyama K, Tezuka T, Kotani M, et al. NYAP: a phosphoprotein family that links PI3K to WAVE1 signalling in neurons. EMBO J 2011; 30(23): 4739-54.
192. Mack TG, Eickholt BJ. New WAVEs in neuronal PI3K signalling. EMBO J 2011; 30(23): 4693-5.
193. Waite K, Eickholt BJ. The neurodevelopmental implications of PI3K signaling. Curr Top Microbiol Immunol 2010; 346: 245-65.
194. Newhall KJ, Criniti AR, Cheah CS, et al. Dynamic anchoring of PKA is essential during oocyte maturation. Curr Biol 2006; 16(3): 321-7.
195. Aye TT, Soni S, van Veen TA, et al. Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol 2012; 52(2): 511-8.
196. Panza E, Gimelli G, Passalacqua M, et al. The breakpoint identified in a balanced de novo translocation t(7;9)(p14.1;q31.3) disrupts the A-kinase (PRKA) anchor protein 2 gene (AKAP2) on chromosome 9 in a patient with Kallmann syndrome and bone anomalies. Int J Mol Med 2007; 19(3): 429-35.
197. Kritzer MD, Li J, Passariello CL, et al. The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ Heart Fail 2014; 7(4): 663-72.
198. Bauman AL, Michel JJ, Henson E, Dodge-Kafka KL, Kapiloff MS. The mAKAP signalosome and cardiac myocyte hypertrophy. IUBMB Life 2007; 59(3): 163-9.
199. Ahmad F, Shen W, Vandeput F, et al. Regulation of Sarcoplasmic Reticulum Ca2+ ATPase 2 (SERCA2) Activity by Phosphodiesterase 3A (PDE3A) in Human Myocardium: PHOSPHORYLATION- DEPENDENT INTERACTION OF PDE3A1 WITH SERCA2. J Biol Chem 2015; 290(11): 6763-76.
200. Yang Y, Mahaffey CL, Berube N, Frankel WN. Interaction between fidgetin and protein kinase A-anchoring protein AKAP95 is critical for palatogenesis in the mouse. J Biol Chem 2006; 281(31): 22352-9.
201. Milne RL, Burwinkel B, Michailidou K, et al. Common nonsynonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2014; 23(22): 6096-111.
202. Schimenti KJ, Feuer SK, Griffin LB, et al. AKAP9 is essential for spermatogenesis and sertoli cell maturation in mice. Genetics 2013; 194(2): 447-57.
203. Chen L, Marquardt ML, Tester DJ, Sampson KJ, MJ Ackerman, RS Kass. Mutation of an A-kinase-anchoring protein causes long- QT syndrome. Proc Natl Acad Sci USA 2007; 104(52): 20990-5.
204. Tingley WG, Pawlikowska L, Zaroff JG, et al. Gene-trapped mouse embryonic stem cell-derived cardiac myocytes and human genetics implicate AKAP10 in heart rhythm regulation. Proc Natl Acad Sci USA 2007; 104(20): 8461-6.
205. Kammerer S, Burns-Hamuro LL, Ma Y, et al. Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc Natl Acad Sci USA 2003; 100(7): 4066-71.
206. Logue JS, Whiting JL, Tunquist B, et al. AKAP220 protein organizes signaling elements that impact cell migration. J Biol Chem 2011; 286(45): 39269-81.
207. Garnis C, Rosin MP, Zhang L, Lam WL. Alteration of AKAP220, an upstream component of the Rb pathway, in oral carcinogenesis. Int J Cancer 2005; 116(5): 813-9.
208. Akakura S, C Huang, PJ Nelson, B Foster, IH Gelman. Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res 2008; 68(13): 5096-103.
209. Mayers CM, Wadell J, McLean K, et al. The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice. J Biol Chem 2010; 285(16): 12344-54.
210. Harada A, Teng J, Takei Y, Oguchi K, Hirokawa N. MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. J Cell Biol 2002; 158(3): 541-9.
211. Pescucci C, Meloni I, Bruttini M, et al. Chromosome 2 deletion encompassing the MAP2 gene in a patient with autism and Rettlike features. Clin Genet 2003; 64(6): 497-501.
212. Prasad SC, Azeez A, Thada ND, Rao P, Bacciu A, Prasad KC. Branchial anomalies: diagnosis and management. Int J Otolaryngol 2014; 2014: 237015.
213. Davies VJ, Hollins AJ, Piechota MJ, et al. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet 2007; 16(11): 1307-18.
214. Yu-Wai-Man P, Griffiths PG, Gorman GS, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010; 133(Pt 3): 771-86.
215. Gold MG, Lygren B, Dokurno P, et al. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell 2006; 24(3): 383-95.
216. Kinderman FS, Kim C, von Daake S, et al. A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol Cell 2006; 24(3): 397-408.
217. Taylor SS, Kim C, Cheng CY, Brown SH, Wu J, Kannan N. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim Biophys Acta 2008; 1784(1): 16-26.
218. Newlon MG, Roy M, Morikis D, et al. A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes. EMBO J 2001; 20(7): 1651-62.
219. Newlon MG, Roy M, Morikis D, et al. The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol 1999; 6(3): 222-7.
220. Carr DW, Stofko-Hahn RE, Fraser ID, et al. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J Biol Chem 1991; 266(22): 14188-92.
221. Schafer G, Milic J, Eldahshan A, et al. Highly functionalized terpyridines as competitive inhibitors of AKAP-PKA interactions. Angew Chem Int Ed Engl 2013; 52(46): 12187-91.
222. Sarma GN, Kinderman FS, Kim C, et al. Structure of DAKAP2: PKA RI complex: insights into AKAP specificity and selectivity. Structure 2010; 18(2): 155-66.
223. Vijayaraghavan S, Liberty GA, Mohan J, Winfrey VP, Olson GE, Carr DW. Isolation and molecular characterization of AKAP110, a novel, sperm-specific protein kinase A-anchoring protein. Mol Endocrinol 1999; 13(5): 705-17.
224. Hundsrucker C, Skroblin P, Christian F, et al. Glycogen synthase kinase 3beta interaction protein functions as an A-kinase anchoring protein. J Biol Chem 2010; 285(8): 5507-21.
225. Burgers PP, van der Heyden MA, Kok B, Heck AJ, Scholten A. A systematic evaluation of protein kinase A - A-kinase anchoring protein interaction motifs. Biochemistry 2014; 54(1): 11-21.
226. McSorley T, E Stefan, V Henn, et al. Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. Euro J Cell Biol 2006; 85(7): 673-8.
227. Gold MG, Smith FD, Scott JD, Barford D. AKAP18 contains a phosphoesterase domain that binds AMP. J Mol Biol 2008; 375(5): 1329-43.
228. Horner A, Goetz F, Tampe R, Klussmann E, Pohl P. Mechanism for targeting the A-kinase anchoring protein AKAP18delta to the membrane. J Biol Chem 2012; 287(51): 42495-501.
229. Smith FD, Reichow SL, Esseltine JL, et al. Intrinsic disorder within an AKAP-protein kinase A complex guides local substrate phosphorylation. Elife 2013; 2: e01319.
230. Gold MG, Stengel F, Nygren PJ, et al. Architecture and dynamics of an A-kinase anchoring protein 79 (AKAP79) signaling complex. Proc Natl Acad Sci USA 2011; 108(16): 6426-31.
231. Li H, Pink MD, Murphy JG, Stein A, Dell'Acqua ML, Hogan PG. Balanced interactions of calcineurin with AKAP79 regulate Ca2+- calcineurin-NFAT signaling. Nat Struct Mol Biol 2012; 19(3): 337-45.
232. Schott MB, Grove B. Receptor-mediated Ca2+ and PKC signaling triggers the loss of cortical PKA compartmentalization through the redistribution of gravin. Cell Signal 2013; 25(11): 2125-35.
233. Rawe VY, Payne C, Navara C, Schatten G. WAVE1 intranuclear trafficking is essential for genomic and cytoskeletal dynamics during fertilization: cell-cycle-dependent shuttling between M-phase and interphase nuclei. Dev Biol 2004; 276(2): 253-67.
234. Smith KE, Gibson ES, Dell'Acqua ML. cAMP-dependent protein kinase postsynaptic localization regulated by NMDA receptor activation through translocation of an A-kinase anchoring protein scaffold protein. J Neurosci 2006; 26(9): 2391-402.
235. Aittaleb M, Boguth CA, Tesmer JJ. Structure and function of heterotrimeric G protein-regulated Rho guanine nucleotide exchange factors. Mol Pharmacol 2010; 77(2): 111-25.
236. Zheng Y. Dbl family guanine nucleotide exchange factors. Trends Biochem Sci 2001; 26(12): 724-32.
237. Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene 2013; 33(31): 4021-35.
238. Abdul Azeez KR, Knapp S, Fernandes JM, Klussmann E, Elkins JM. The Crystal Structure of the RhoA: AKAP-Lbc DH-PH Domain Complex. Biochem J 2014; 464(2): 231-9.
239. Alto NM, Soderling SH, Hoshi N, et al. Bioinformatic design of Akinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proc Natl Acad Sci USA 2003; 100(8): 4445-50.
240. Carlson CR, Lygren B, Berge T, et al. Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem 2006; 281(30): 21535-45.
241. Burns-Hamuro LL, Ma Y, Kammerer S, et al. Designing isoformspecific peptide disruptors of protein kinase A localization. Proc Natl Acad Sci USA 2003; 100(7): 4072-7.
242. Gold MG, Fowler DM, Means CK, et al. Engineering A-kinase anchoring protein (AKAP)-selective regulatory subunits of protein kinase A (PKA) through structure-based phage selection. J Biol Chem 2013; 288(24): 17111-21.
243. Hulme JT, Ahn M, Hauschka SD, Scheuer T, Catterall WA. A novel leucine zipper targets AKAP15 and cyclic AMP-dependent protein kinase to the C terminus of the skeletal muscle Ca2+ channel and modulates its function. J Biol Chem 2002; 277(6): 4079-87.
244. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013; 81(1): 136-47.
245. Jin L, Wang W, Fang G. Targeting protein-protein interaction by small molecules. Annu Rev Pharmacol Toxicol 2014; 54: 435-56.
246. Higueruelo AP, Jubb H, Blundell TL. Protein-protein interactions as druggable targets: recent technological advances. Curr Opin Pharmacol 2013; 13(5): 791-6.
247. Schachterle C, Christian F, Fernandes JM, Klussmann E. Screening for small molecule disruptors of AKAP-PKA interactions. Methods Mol Biol 2015; 1294: 151-66.
248. Yu X, Li F, Klussmann E, Stallone JN, Han G. G protein-coupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. Am J Physiol Endocrinol Metab 2014; 307(4): E398-407.
249. Torheim EA, Jarnaess E, Lygren B, Tasken K. Design of proteolytically stable RI-anchoring disruptor peptidomimetics for in vivo studies of anchored type I protein kinase A-mediated signalling. Biochem J 2009; 424(1): 69-78.
250. McConnell BK, Popovic Z, Mal N, et al. Disruption of protein kinase A interaction with A-kinase-anchoring proteins in the heart in vivo: effects on cardiac contractility, protein kinase A phosphorylation, and troponin I proteolysis. J Biol Chem 2009; 284(3): 1583-92.
251. Patel HH, Hamuro LL, Chun BJ, et al. Disruption of protein kinase A localization using a trans-activator of transcription (TAT)- conjugated A-kinase-anchoring peptide reduces cardiac function. J Biol Chem 2010; 285(36): 27632-40.
252. Burton KA, Johnson BD, Hausken ZE, et al. Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinase. Proc Natl Acad Sci USA 1997; 94(20): 11067-72.
253. Faruque OM, Le-Nguyen D, Lajoix AD, et al. Cell-permeable peptide-based disruption of endogenous PKA-AKAP complexes: a tool for studying the molecular roles of AKAP-mediated PKA subcellular anchoring. Am J Physiol Cell Physiol 2009; 296(2): C306-16.
254. Wang Y, Ho TG, Bertinetti D, et al. Isoform-selective disruption of AKAP-localized PKA using hydrocarbon stapled peptides. ACS Chem Biol 2014; 9(3): 635-42.
255. Wang Y, Ho TG, Franz E, et al. PKA-type I selective constrained peptide disruptors of AKAP complexes. ACS Chem Biol 2015; 10(6): 1502-10.
256. Yu X, Li F, Klussmann E, Stallone JN, Han G. G protein-coupled estrogen receptor 1 (GPER) mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. Am J Physiol Endocrinol Metab 2014; 307(4): E398-407.
257. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63(12): 1123-33.
258. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol 2014; 171(3): 368-76.
259. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103(2): 137-49.
260. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics - developing a new class of drugs. Nat Rev Drug Discov 2014; 13(10): 759-80.
261. Ivanov AA, Khuri FR, Fu H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci 2013; 34(7): 393-400.
262. Bavec A. (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins. Life Sci 2014; 99(1-2): 7-13.
263. Nystoriak MA, Nieves-Cintron M, Nygren PJ, et al. AKAP150 contributes to enhanced vascular tone by facilitating largeconductance Ca2+-activated K+ channel remodeling in hyperglycemia and diabetes mellitus. Circ Res 2014; 114(4): 607-15.
264. Sonkusare SK, Dalsgaard T, Bonev AD, et al. AKAP150- dependent cooperative TRPV4 channel gating is central to endothelium- dependent vasodilation and is disrupted in hypertension. Sci Signal 2014; 7(333): ra66.
265. Lefkimmiatis K, Zaccolo M. cAMP signaling in subcellular compartments. Pharmacol Ther 2014; 143(3): 295-304.